OHSU

IRB #

IRB00009761

Title

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma.

Principal Investigator

Emma Scott

Study Purpose

The purpose of the study is to determine whether adding the study drug, MLN9708, to the combination of lenalidomide and dexamethason improves survival in patients with newly diagnosed multiple myeloma (MM).

Medical Condition(s)

Multiple Myeloma

Eligibility Criteria

Inclusion criteria:
1) Adults 18 years of age or older
2) Patients whom lenalidomide and dexamethason treatment is appropriate and who are not eligible for stem cell transplant due to age or health conditions
3) Confirmed diagnosis of multiple myeloma
Exclusion:
1) Prior treatment for multiple myeloma
2) Another type of cancer within the last 5 years
3) Any current uncontrolled condition or infection
4) Pregnant or breastfeeding women

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Up to 87 months

Minors Included

No

Contact

Nan Subbiah
(503) 494-4603

Sponsor

Millennium Pharmaceuticals, Inc

Recruitment End

08/28/2020

Compensation Provided

No


Go Back